| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/21/2009 | US7521450 Inhibitors of kinases |
| 04/21/2009 | US7521419 Peptide-based compounds |
| 04/21/2009 | US7521239 Method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the |
| 04/21/2009 | US7521215 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents |
| 04/21/2009 | US7521212 Method for producing oligopolysaccharides |
| 04/21/2009 | US7521181 Methods of diagnosing risk of myocardial infarction by detection of polymorphisms in connexin and NADH/NADPH oxidase genes |
| 04/21/2009 | US7521068 For pulmonary and nasal drug administration |
| 04/21/2009 | US7521053 Angiopoietin-2 specific binding agents |
| 04/21/2009 | US7521046 Antibody immunization therapy for treatment of atherosclerosis |
| 04/21/2009 | CA2362003C Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/21/2009 | CA2356263C Aminopyrazole derivatives |
| 04/21/2009 | CA2309038C Use of inhaled no as anti-inflammatory agent |
| 04/21/2009 | CA2299420C Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use |
| 04/21/2009 | CA2228038C 2(1h)-quinolone derivatives, their preparation and their use in therapy |
| 04/21/2009 | CA2182949C Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/21/2009 | CA2157855C Benzoylguanidines substituted by heterocyclic n-oxide, process for their preparation, their use as a medicament or diagnostic agent, medicament containing them and intermediate products for their preparation |
| 04/16/2009 | WO2009048540A1 Method and composition for treating heart failure |
| 04/16/2009 | WO2009048166A1 Therapeutic agent for heart disease, which is intended to be used in cell transplantation therapy |
| 04/16/2009 | WO2009048148A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 04/16/2009 | WO2009047826A2 Pharmaceutical composition comprising sucralphate and mesalazine |
| 04/16/2009 | WO2009047654A1 Low sodium salt replacing composition for use in food products, nutraceuticals and pharmaceuticals |
| 04/16/2009 | WO2009047637A1 Novel polymorphs of bosentan |
| 04/16/2009 | WO2009047359A1 Inhibitors of protein kinases |
| 04/16/2009 | WO2009047330A1 Use of wnt5a for treating or preventing obesity and atherosclerosis |
| 04/16/2009 | WO2009047240A1 Indole derivatives useful as ppar activators |
| 04/16/2009 | WO2009047101A1 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders |
| 04/16/2009 | WO2009046881A1 Use of a peptide combination including c-peptide, as a therapeutic agent |
| 04/16/2009 | WO2009046880A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046879A2 Use of the combination of npy and nociceptin as a therapeutic agent |
| 04/16/2009 | WO2009046878A1 Tnf inhibitory peptide and cgrp as therapeutic agents |
| 04/16/2009 | WO2009046877A2 Use of a histrelin and leuprolide as therapeutic agents |
| 04/16/2009 | WO2009046876A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046875A2 Combination of splenopentin and thymopentin and the use thereof in medicine |
| 04/16/2009 | WO2009046874A1 Therapeutic combination of trh-potentiating peptide and stresscopin |
| 04/16/2009 | WO2009046873A1 Combined use of vasonatrin and gastrin-i as a therapeutic agent |
| 04/16/2009 | WO2009046872A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046868A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046867A2 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 04/16/2009 | WO2009046866A2 Trap-14 as a therapeutic agent |
| 04/16/2009 | WO2009046865A2 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 04/16/2009 | WO2009046864A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046863A2 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046862A1 Use of physalemin as a therapeutic agent |
| 04/16/2009 | WO2009046861A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | WO2009046860A2 Use of dago as a therapeutic agent |
| 04/16/2009 | WO2009046859A2 Use of af12198 and dago as therapeutic agents |
| 04/16/2009 | WO2009046858A2 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 04/16/2009 | WO2009046857A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046856A2 Use of serorphin as a therapeutic agent |
| 04/16/2009 | WO2009046853A1 Use of intermedin 47 peptide as a therapeutic agent |
| 04/16/2009 | WO2009046852A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | WO2009046850A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046849A1 Use of the peptide cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046848A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046847A2 Use of peptide ll-37 as a therapeutic agent |
| 04/16/2009 | WO2009046846A2 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 04/16/2009 | WO2009046845A2 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 04/16/2009 | WO2009046844A1 Therapeutic uses of peptide tdvngdgrhdl |
| 04/16/2009 | WO2009046843A1 Therapeutic uses of peptides kvlpvpq and/or tdvngdgrhdl |
| 04/16/2009 | WO2009046835A1 Use of goserelin and amylin as therapeutic agents |
| 04/16/2009 | WO2009046834A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/16/2009 | WO2009046833A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046832A2 Short peptides used in medicine |
| 04/16/2009 | WO2009046831A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046830A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046829A2 Casoxin d as a therapeutic agent |
| 04/16/2009 | WO2009046827A2 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents |
| 04/16/2009 | WO2009046825A1 Use of a peptide acetyl-calpastatin as a therapeutic agent |
| 04/16/2009 | WO2009046824A2 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis |
| 04/16/2009 | WO2009046823A1 Exendin-3 and apelin-12 for therapeutic applications |
| 04/16/2009 | WO2009046822A2 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 04/16/2009 | WO2009046620A1 Cycloastragenol monoglucoside, preparation, pharmaceutical composition and application thereof |
| 04/16/2009 | WO2009007112A3 Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction |
| 04/16/2009 | WO2008148849A3 Piperidine/piperazine derivatives |
| 04/16/2009 | WO2008135795A3 Polymorphic forms of bosentan |
| 04/16/2009 | WO2008040002A9 Methods, compositions and articles of manufacture for hif modulating compounds |
| 04/16/2009 | WO2006127007A3 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| 04/16/2009 | WO2005042727A3 Methods of organ regeneration |
| 04/16/2009 | WO2003082205A3 Compounds and methods |
| 04/16/2009 | US20090099373 Compositions enriched in anthocyanins |
| 04/16/2009 | US20090099341 Heparanase specific molecular probes and their use in research and medical applications |
| 04/16/2009 | US20090099261 Omega-3 mixtures |
| 04/16/2009 | US20090099256 Drug for Treating Circulatory Insufficiency |
| 04/16/2009 | US20090099255 Agent for Alleviating Vascular Failure |
| 04/16/2009 | US20090099254 Method and Kit for Regulation of Microvascular Tone |
| 04/16/2009 | US20090099241 Pharmaceutical composition containing antihypertensive agents |
| 04/16/2009 | US20090099240 Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
| 04/16/2009 | US20090099231 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors |
| 04/16/2009 | US20090099219 Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 04/16/2009 | US20090099211 Treatments for congestive heart failure |
| 04/16/2009 | US20090099207 Cyclic sulfones useful as BACE inhibitors |
| 04/16/2009 | US20090099190 Kinase inhibitors useful for the treatment of proliferative diseases |
| 04/16/2009 | US20090099184 Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| 04/16/2009 | US20090099176 Pyrrolopyridine-2-carboxylic acid amides |
| 04/16/2009 | US20090099171 Diazaquinolones that inhibit prolyl hydroxylase activity |
| 04/16/2009 | US20090099162 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias |
| 04/16/2009 | US20090099157 Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
| 04/16/2009 | US20090099139 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 04/16/2009 | US20090099137 Anti-Inflammatory Compounds and Uses Thereof |
| 04/16/2009 | US20090099100 Compositions and methods for treating amyloidosis |